<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02520934</url>
  </required_header>
  <id_info>
    <org_study_id>201503076MIPD</org_study_id>
    <nct_id>NCT02520934</nct_id>
  </id_info>
  <brief_title>Miglustat on Gaucher Disease Type IIIB</brief_title>
  <official_title>Evaluation of Combination Therapy With Miglustat and Enzyme Replacement Therapy on Gaucher Disease Type IIIB</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      evaluate the combination therapy with Miglustat and enzyme replacement therapy (ERT) on
      Gaucher disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      understand if Miglustat (glucosylceramide synthase inhibitor) could improve neuropathy in
      patients with Gaucher disease
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improve in Purdue Pegboard test speed</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Gaucher Disease</condition>
  <arm_group>
    <arm_group_label>Case_Miglustat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Besides regular ERT, patients in this group also need to take Miglustat for 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will be tested for their pupil cycle time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Miglustat</intervention_name>
    <description>combine miglustat and ERT to see if neurologic manifestations can be improved</description>
    <arm_group_label>Case_Miglustat</arm_group_label>
    <other_name>Zavesca</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ERT</intervention_name>
    <description>enzyme replacement therapy</description>
    <arm_group_label>Case_Miglustat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Case_Miglustat

        Inclusion Criteria:

          1. Confirmed diagnosis of Gaucher Disease: blood test shown lack of beta-
             glucocerebrosidase, and found L444P homozygous on GBA gene.

          2. Aged 6 years old or above.

          3. Already have regular ERT (30-120 IU/kg/ every 2 weeks) at least a year; dosage and
             frequency of ERT had not been changed in recent 3 months.

        Exclusion Criteria:

          1. History of tremor and abnormal extremities perception ( pain, numbness, tingle etc.)

          2. Abnormal kidney function.

          3. Pregnant or plan to have a baby ( potentially pregnant patient need to be transferred
             to gynecologist for the test and promise to have proper contraception measures).

          4. Allergic to Miglustat.

        Control_normal Inclusion Criteria

          1. Age 6-18 years

          2. No significant physical, mental, or psychiatric problems

        Exclusion criteria

        1. Children with eye disease (not include myopia, hyperopia, Astigmatism)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yin-Hsiu Chien, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10041</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2015</study_first_submitted>
  <study_first_submitted_qc>August 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2015</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Enzyme Replacement Therapy</keyword>
  <keyword>Miglustat</keyword>
  <keyword>Gaucher Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaucher Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Miglustat</mesh_term>
    <mesh_term>1-Deoxynojirimycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

